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Abstract
Introduction: Thrombosis in myeloproliferative thrombocytosis occurs usually in the microvessels and medium-
sized arteries and veins and only rarely in the aorta. Aortic thrombosis is usually treated with thrombectomy.
Reported here is a rare case that was treated pharmacologically.
Case presentation: A 60-year-old Japanese woman presented with numbness of both lower extremities. Her
platelet count was 1787 × 10
3/μl. Through bone marrow examination, we diagnosed her condition as
myelodysplastic and/or myeloproliferative disorder-unclassifiable. Abdominal ultrasonography and computed
tomographic scan revealed aortic thrombosis. Her platelet count was controlled with hydroxyurea and ranimustine.
Aspirin and ticlopidine improved the numbness in both lower limbs on the second day. Aortic thrombosis was not
observed in a computed tomographic scan on the seventh day.
Conclusion: For aortic thrombosis, surgical management is usually adopted, but pharmacological management is
also an option because of its immediate curative effects.
Introduction
Thrombocytosis is classified into myeloproliferative
thrombocytosis and reactive thrombocytosis. In myelo-
proliferative thrombocytosis, there is always a risk of
thrombosis. It is well known that thrombosis in myelo-
proliferative thrombocytosis occurs in the medium-sized
arteries and veins and in the microvessels [1]. However,
aortic thrombosis is rare [2,3]. We report a rare case of
aortic thrombosis with myeloproliferative thrombocyto-
sis. The main therapeutic method to resolve aortic
thrombosis is a thrombectomy [4,5]. However, the aortic
thrombus in our case was treated immediately pharma-
cologically. This case may serve as a reference for the
choice of therapy for aortic thrombosis.
Case presentation
A 60-year-old Japanese woman presented with numb-
ness in both lower extremities. This symptom appeared
four months prior to admission, and she experienced
giddiness two months before. However, she had ignored
these symptoms. Her medical history revealed that she
had undergone an oophorectomy, and she had a uterine
s a r c o m aa tt h ea g eo f3 6a n dm a s t i t i sa tt h ea g eo f4 5 .
Her consciousness was clear but she had anaemic con-
junctivae. Physical examination revealed that she was a
well-nourished female with normal vital signs. She had
no chest pain. Her liver and spleen were not palpable.
Although she experienced numbness in both her lower
limbs, the neurological findings were normal, and
neither extremity was cold.
The patient had a white-blood-cell count of 2.74 ×
10
3/μl with 37% neutrophils, 62% lymphocytes and 1%
monocytes. Her haemoglobin level was 7.8 g/dl and her
platelet count was 1787 × 10
3/μl. Examination of bone-
marrow aspirate revealed normal cellular marrow, mega-
karyocytic hyperplasia and erythroid dysplasia. Her kar-
yogram was normal.
Abdominal ultrasonography revealed in the aorta a
moveable mass with a diameter of 1.5 cm. The interior
of the mass had no blood supply. A computed tomo-
graphic scan of her abdomen revealed a circular throm-
bus in the descending aorta at the level of the * Correspondence: hide1005@aichi-med-u.ac.jp
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nized at that point.
We diagnosed this case of thrombocytosis and anemia
as myelodysplastic syndrome and/or myeloproliferative
disorder-unclassifiable (MDS/MPD-U), and the aortic
thrombus was thought to be associated with myeloproli-
ferative thrombocytosis.
For myeloproliferative thrombocytosis, she was treated
with 500 mg of hydroxyurea from the seventh day of
her hospital stay. However, she was administered 1000
mg of hydroxyurea on the 16
th day because her platelet
count increased to 2074 × 10
3/μl. In addition, she was
administered 50 mg of ranimustine on the 18
th day. The
platelet count decreased to 274 × 10
3 /μlo nt h e3 9
th
day, but it increased slowly thereafter. After administra-
tion of 1000 mg of hydroxyurea, her platelet count sta-
bilized at approximately 1000 × 10
3/μl. She was
administered transfusions for anemia.
Ticlopidine was administered to prevent the develop-
ment of a thrombosis on the seventh hospital day,
which was the same day treatment for myeloproliferative
thrombocytosis was initiated. Aspirin (100 mg) was
administered when an aortic thrombus was identified by
computed tomographic scan on the 10
th day of her hos-
pital stay. The numbness in both of her lower extremi-
ties disappeared within two days. Also, the aortic
thrombus was not observed in the computed tomo-
graphic scan on the 17
th day of her hospital stay. She
was administered aspirin after seven days (Figure 2). She
has been without symptoms for more than one year.
Discussion
MDS is haematological monoclonal disease character-
ized by dysplasia and ineffective haematopoiesis, which
causes cytopenia [6]. Chronic myeloproliferative disor-
ders (CMPD) are also haematological monoclonal
diseases. However, they are characterized by an increase
i nt h en u m b e ro fm o r et h a no n et y p eo fm y e l o i dl i n e -
age. There is a disease group that borders or overlaps
both the MDS and CMPD disease groups. The World
Health Organization (WHO) defined MDS/MPD in
2001 [7]. MDS/MPDs were classified as chronic myelo-
monocytic leukaemia, atypical chronic myeloid leukae-
mia, juvenile myelomonocytic leukaemia and
myelodysplastic and/or myeloproliferative disorders-
unclassifiable (MPD/MDS-U). MDS/MPD-U fails to
meet the criteria for any of the specific MPD/MDS enti-
ties. On one hand, it is characterized by dysplasia and
ineffective haematopoiesis, and on the other hand, it is
characterized by an increase in the number of more
than one type of myeloid lineage. A representative disor-
der of this group of diseases is refractory anaemia with
ringed sideroblasts (MDS-RARS), wherein the platelet
count is over 600 × 10
3/μl [8]. The symptoms in this
case are similar to those in the case of MDS-RARS and
it satisfies the criteria for MPD/MDS; however, this case
cannot precisely be diagnosed as MDS-RARS because
Prussian blue reaction was not performed. The new
WHO classification was published in September 2008
[9]. As for MDS/MPD, the name was changed to myelo-
dysplastic and/or myeloproliferative neoplasm (MDS/
MPN). According to the new classification, this case is a
case of MDS/MPN-U.
It is well known that thrombosis occurs in medium-
sized vessels and in microvessels in myeloproliferative
thrombocytosis [1]. Of these thrombosis cases, including
cases of cerebral infarction, transient cerebral ischaemic
attack, retinal thrombosis, ischaemic heart disease, pul-
monary infarction, hepatic artery and portal vein throm-
bosis, deep venous thrombosis and ischaemia of limbs,
11% to 25% are included in the myeloproliferative
thrombocytosis group [10]. However, cases of aortic
Figure 1 Enhanced computed tomography scan before treatment. A thrombus is observed in the lower-line aortic blood vessel at the level
of the diaphragm.
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thrombocytosis cases [2,3]. Therefore, the stipulated
treatment has not been established.
The prognosis of patients with myeloproliferative
thrombocytosis is mainly determined by the onset of
thrombosis; therefore, it is very important to control
thrombosis [11]. Usually, in a case of aortic thrombosis,
surgical management is adopted as the main therapy,
and therapy in the form of medication is rare.
Johnson et al reported an essential thrombocythaemia-
associated intra-aortic thrombus that was treated with
an aortic thrombectomy, and they removed the throm-
bus, which consisted of platelets [4]. Sohn et al also
described a case of surgical management [5]. This treat-
ment is advantageous as surgical management prevents
necrosis in the organ by an embolism in the peripheral
arteries. However, aortic thrombectomy is a risky proce-
dure. Ehrenfeld et al reported the case of a patient who
died of shock after an aortic thrombectomy for throm-
bocytosis [12].
On the other hand, Fang et al reported a large aortic
thrombus with essential thrombocythaemia that was
treated with medication, and to the best of our knowl-
edge, this is the only case in which this was done [13].
In this case, the symptoms disappeared within two days
(similar to our case), and the disappearance of the
thrombus was confirmed three weeks later by computed
tomography. In our case, we confirmed the resolution of
the thrombus eight days later. Because the symptoms
disappeared within two days in both cases, the resolu-
tion of the thrombus might have occurred at similar
times in both cases. If the thrombus can be dissolved
early by pharmacological treatment, we believe that not
only aortic thrombectomy but also pharmacological
treatment can prevent necrosis in the organ. This
implies that pharmacological treatment can be used as
the primary treatment for this condition in the future.
Johnson et al identified a thrombus comprising platelets;
this thrombus was termed a ‘white clot’ due to the charac-
teristic thrombocythaemia [4]. Therefore, it is logical to
treat patients with aspirin which is a cyclooxygenase
(COX) inhibitor. Aspirin disrupts thromboxan A2 produc-
tion by inhibiting COX-1 of the arachidonic acid cascade,
and it exhibits antiplatelet action [14]. In particular, sec-
ondary aggregation, most of which result in the formation
of large thrombi, such as an aortic thrombosis, is pre-
vented. On the other hand, ticlopidine prevents platelet
aggregation by specifically obstructing the adenosine
diphosphate receptor P2Y12 [15]. In addition, it prevents
shear-induced platelet aggregation. This case indicated
that the combination of aspirin and ticlopidine can act
synergistically because of their different mechanisms. In
this case, there is a possibility that two types of antiplatelet
agents contributed to early action.
This case showed that antiplatelet medications are
effective for aortic thrombosis, and this case may serve as
a reference in the choice of therapy for aortic thrombosis.
Conclusion
We report an aortic thrombosis case with myeloproli-
ferative thrombocytosis treated by medical management.
Thus far, surgical management has been adopted for
such cases. However, this report suggests that medical
management is a safe and effective strategy for aortic
thrombosis in the case of myeloproliferative
thrombocytosis.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
Figure 2 Enhanced computed tomography scan after seven days of treatment. The circular thrombus has disappeared. However, there is a
low density area in the same spot, which was identified as a wall thrombosis.
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